Drugs Habits and Social Policy
May 27, 2026
Estelle Miller, David B Menkes, Suresh Muthukumaraswamy et al.
Purpose Current laws prohibiting access to illicit drugs contribute to drug harms as manufacturers and distributors of illicit substances have variable influence over drug supply and quality. Legislation introduced in New Zealand (NZ) in 2021 aimed to address such harm by enabling licenced drug checking providers to directly analyse samples from consumers. This paper aims to detail the use of...
Journal of Psychedelic Studies
January 6, 2026
Tobias Erny, Elba Yatziri Cano Montenegro, Joern Barth et al.
Abstract Background and Aims Parkinson's disease (PD) significantly impairs quality of life, and current treatments do not halt dopaminergic neurodegeneration. Evidence suggests that ibogaine, a naturally occurring indole alkaloid, may stimulate glial cell line-derived neurotrophic factor (GDNF) expression and affect dopamine transporter (DAT) function. This case study reports the effects of...
Harm Reduction Journal
May 23, 2024
Jai Whelan, Ryan D Ward, Geoff Noller
2 citations
Methylenedioxymethamphetamine (MDMA) is a popular drug worldwide and use is prevalent in Aotearoa New Zealand. Although associated with some significant harms, including fatalities, MDMA is ultimately less harmful than other commonly consumed drugs. We aimed to expand the understanding of MDMA harm and harm reduction strategies from a consumer perspective so that national harm reduction efforts...
Harm Reduction Journal
March 21, 2024
Jai Whelan, Geoff Noller, Ryan D Ward
6 citations
3,4-Methylenedioxymethamphetamine (MDMA) is drug of high prevalence in Aotearoa New Zealand and is the primary drug analysed by legal drug checking services. We aimed to address the gap in literature pertaining to MDMA-related harm reduction behaviour and harm experiences within the country. An online survey was used to assess the harm reduction behaviours (e.g., limiting consumption, planning...
Drug Science, Policy and Law
2024
Jai Whelan, Geoff Noller, Ryan D Ward
The prevalence of 3,4-methylenedioxymethamphetamine (MDMA) consumption is relatively high in Aotearoa New Zealand, but MDMA use has not been investigated in detail. We explored consumption behaviours and a range of MDMA-related factors, including motivations, subjective effects, and reflections about personal MDMA use via a cross-sectional survey. A total of 1180 respondents (59.2% female, 15%...
Journal of Psychoactive Drugs
2019
Thomas K Brown, Geoff Noller, Julie O Denenberg
48 citations
This article examines the therapeutic potential of ibogaine, a powerful oneiric alkaloid derived from Tabernanthe iboga, through exploring the subjective experiences of 44 participants from two observational treatment studies for opioid use disorder. Following treatment with ibogaine HCl, the participants (Mexico, n = 30; New Zealand, n = 14) completed the States of Consciousness Questionnaire...